Telix Pharmaceuticals Limited announced completion of patient enrollment in the Phase 3 BiPASS™ study of its commercial PSMA-PET imaging agent...
Vector Science and Therapeutics Corp. ("Vector" or the "Company") is pleased to announce that the Company has entered into an investo...
Skye Bioscience, Inc., and Redx Pharma Limited (“Redx”), a U.K. based, privately-held clinical-stage biotechnology company focused on develop...
Merck has reported strong financial results for the second quarter of 2026, driven by sustained growth across its Life Science and Electronics businesses...
Curium™ announced it is advancing plans for a second cyclotron investment in Romania, reaffirming the company’s long-term commitment to expan...
Lundbeck announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Lu AH69593, the company's lead oral orexin 2 rece...
The issuer is solely responsible for the content of this announcement. Fresenius is further expanding its access to innovation networks through its own co...
A consortium of European and US-based investors and Nobias Therapeutics announced the launch of Synaptiq Therapeutics, a privately held, clinical-stage bio...
The Alberta Cancer Foundation is investing $35-million to advance cancer clinical trials in Alberta. The amount represents one of the largest investment...
Financing will accelerate the development of human-relevant biological data infrastructure, virtual cell technologies, and next-generation drug discovery...
Siren Biotechnology, pioneers of Universal AAV Immuno-Gene Therapy for cancer, announced that the California Institute for Regenerative Medicine (C...
Biogen Inc. (Nasdaq: BIIB) and RayThera Inc., a private biotechnology company focused on discovering and developing small molecule therapies in immunolog...
Senior secured term loan of up to CHF 250 million with a 5‑year maturity at a fixed 7% interest rate First tranche will fully refinance the existing...
- Initiation of Phase 3 IMPACT DUCHENNE placebo-controlled, randomized, double-blind trial as part of Solid’s integrated, multi-trial development p...
© 2026 Biopharma Boardroom. All Rights Reserved.
